Press "Enter" to skip to content

Pfizer gets U.S. approval for $225,000 a year heart drug

Pfizer, which has touted tafamidis as a potential blockbuster product, set a list price of $225,000 a year for the medicine, which would be sold under the brand name Vyndaqel.

Original source: https://health.economictimes.indiatimes.com/news/pharma/pfizer-gets-u-s-approval-for-225000-a-year-heart-drug/69201581?utm_source=RSS&utm_medium=ETRSS

Also Read:   Four killed in attacks against Ebola response centers in Congo